Table 3.
Stratified analysis of F5 genes and OS in GC patients.
| Group | Low | High | Crude HR (95% CI) | Crude P value | Adjusted HR (95% CI) | Adjusted P valuea |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <60 | 53 | 55 | 1.315 (0.68, 2.545) | 0.416 | 1.878 (0.883, 3.994) | 0.102 |
| ≥60 | 121 | 119 | 1.459 (0.996, 2.136) | 0.052 | 1.446 (0.949, 2.202) | 0.086 |
| Pathological T | ||||||
| T 1/2 | 52 | 39 | 1.332 (0.632, 2.805) | 0.451 | 1.164 (0.483, 2.806) | 0.735 |
| T 3/4 | 120 | 136 | 1.39 (0.96, 2.01) | 0.81 | 1.56 (1.043, 2.334) | 0.03 |
| Pathological M | ||||||
| M0 | 11 | 13 | 0.418 (0.128, 1.37) | 0.15 | 13.597 (1.012, 182.75) | 0.049 |
| M1 | 159 | 153 | 1.373 (0.965, 1.953) | 0.078 | 1.357 (0.925, 1.991) | 0.119 |
| TNM stage | ||||||
| Stage I | 28 | 19 | 1.726 (0.51, 5.839) | 0.38 | 7.483 (0.732, 76.529) | 0.09 |
| Stage II | 59 | 50 | 1.28 (0.652, 2.513) | 0.474 | 1.235 (0.625, 2.438) | 0.544 |
| Stage III | 68 | 79 | 1.439 (0.891, 2.324) | 0.137 | 1.318 (0.798, 2.177) | 0.281 |
| Stage IV | 14 | 21 | 1.852 (0.71, 4.83) | 0.207 | 3.856 (1.135, 13.101) | 0.031 |
| Radiation therapy | ||||||
| Yes | 30 | 32 | 3.389 (1.207, 9.522) | 0.021 | 4.607 (1.323, 16.035) | 0.016 |
| No | 137 | 129 | 1.282 (0.89, 1.847) | 0.182 | 1.345 (0.913, 1.981) | 0.133 |
| Targeted molecular therapy | ||||||
| Yes | 85 | 66 | 1.558 (0.919, 2.641) | 0.099 | 1.885 (1.065, 3.338) | 0.03 |
| No | 82 | 93 | 1.3 (0.829, 2.04) | 0.254 | 1.35 (0.839, 2.17) | 0.216 |
| Cancer status | ||||||
| No | 108 | 98 | 2.515 (1.25, 5.061) | 0.01 | 2.852 (1.327, 6.127) | 0.007 |
| Yes | 54 | 64 | 1.366 (0.884, 2.112) | 0.161 | 1.277 (0.801, 2.037) | 0.304 |
aAdjusted for age, TNM stage, radiation therapy, and targeted molecular therapy; the missing patients of these clinical parameters are the same as Table 1. Abbreviations: F5—Coagulation factor V; HR—hazard ratio; OS—overall survival; GC—gastric cancer.